Bausch & Lomb Corp
BLCO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$34.00 | Hmwgvw | Pyqxfhcp |
Restarting Coverage of Bausch & Lomb With $25 Fair Value Estimate
Business Strategy and Outlook
As a new public company, Bausch & Lomb will be primarily focused on ramping up research and development to become more competitive in its key markets of contact lens and solution, eyecare surgery, and ophthalmic pharmaceuticals.